| Revision as of 20:04, 1 September 2011 editCheMoBot (talk | contribs)Bots141,565 edits Updating {{drugbox}} (no changed fields - added verified revid - updated 'ChemSpiderID_Ref', 'UNII_Ref', 'ChEMBL_Ref', 'ChEBI_Ref', 'KEGG_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref', 'ChEBI_Ref') per Chem/Drugbox validation (report [[Wik← Previous edit | Revision as of 10:06, 29 September 2011 edit undo194.133.18.67 (talk) Added what actually happens in the "Response to vaccination" space - I've just had my 2nd injection, so can affirm, this is true!Next edit → | ||
| Line 59: | Line 59: | ||
| People who fail to respond (anti-Hbs antibody level below 10 mIU/ml) should be tested to exclude current or past Hepatitis B infection, and given a repeat course of 3 vaccinations, followed by further retesting 1–4 months after the second course. Those who still do not respond to a second course of vaccination may respond to intradermal administration<ref>{{cite pmid|2148433}}</ref> or to a high dose vaccine <ref>{{Cite pmid|7759824}}</ref> or to a double dose of a combined Hepatitis A and B vaccine.<ref>{{Cite pmid|18544037}}</ref> Those who still fail to respond will require hepatitis B ] (HBIG) if later exposed to the hepatitis B virus.<ref name="isbn0113225288" /> | People who fail to respond (anti-Hbs antibody level below 10 mIU/ml) should be tested to exclude current or past Hepatitis B infection, and given a repeat course of 3 vaccinations, followed by further retesting 1–4 months after the second course. Those who still do not respond to a second course of vaccination may respond to intradermal administration<ref>{{cite pmid|2148433}}</ref> or to a high dose vaccine <ref>{{Cite pmid|7759824}}</ref> or to a double dose of a combined Hepatitis A and B vaccine.<ref>{{Cite pmid|18544037}}</ref> Those who still fail to respond will require hepatitis B ] (HBIG) if later exposed to the hepatitis B virus.<ref name="isbn0113225288" /> | ||
| Poor responses are mostly associated with being over the age of 40 years, obesity and smoking,<ref name="pmid8254852">{{cite doi|10.1001/jama.270.24.2931}}</ref> and also in alcoholics, especially if with advanced liver disease.<ref name="pmid9316554">{{Cite doi|10.1016/S0002-9343(97)00132-0}}</ref> Patients who are immunosuppressed or on renal dialysis may respond less well and require larger or more frequent doses of vaccine.<ref name="isbn0113225288" /> At least one study suggests that hepatitis B vaccination is less effective in patients with HIV.<ref>{{cite doi|10.1186/1471-2334-6-65}} |
Poor responses are mostly associated with being over the age of 40 years, obesity and smoking,<ref name="pmid8254852">{{cite doi|10.1001/jama.270.24.2931}}</ref> and also in alcoholics, especially if with advanced liver disease.<ref name="pmid9316554">{{Cite doi|10.1016/S0002-9343(97)00132-0}}</ref> Patients who are immunosuppressed or on renal dialysis may respond less well and require larger or more frequent doses of vaccine.<ref name="isbn0113225288" /> At least one study suggests that hepatitis B vaccination is less effective in patients with HIV.<ref>{{cite doi|10.1186/1471-2334-6-65}} | ||
| Cold or Flu like symptoms can develop after receiving the vaccine, but these are short lived. As with any injection, the muscle can become tender around the injection point for some time afterwards</ref> | |||
| ==Duration of protection== | ==Duration of protection== | ||
Revision as of 10:06, 29 September 2011
Pharmaceutical compound| Vaccine description | |
|---|---|
| Target | Hepatitis B |
| Vaccine type | Subunit |
| Clinical data | |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a607014 |
| ATC code | |
| (verify) | |
Hepatitis B vaccine is a vaccine developed for the prevention of hepatitis B virus infection. The vaccine contains one of the viral envelope proteins, hepatitis B surface antigen (HBsAg). It is produced by yeast cells, into which the genetic code for HBsAg has been inserted. A course of three (3) vaccine injections are given with the second injection at least one month after the first dose and the third injection given six months after the first dose. Afterward an immune system antibody to HBsAg is established in the bloodstream. The antibody is known as anti-HBsAg. This antibody and immune system memory then provide immunity to hepatitis B infection. The first vaccine became available in 1981.
A range of vaccines are available in the market. Presently recombinant DNA vaccines are available, which means they are produced by inserting the gene for HBV into common baker's yeast where it is grown, harvested, and purified. HBV infection cannot occur from receiving hepatitis B vaccine. The common brands available are Engerix-B (GSK), Elovac B (Human Biologicals Institute, A division of Indian Immunologicals Limited), Genevac B (Serum Institute), Shanvac B etc. These vaccines are given intramuscularly.
The invention
The invention of the vaccine began with the realization (by virologist Alfred Prince, in 1968) that the Australia antigen was part of a virus that caused hepatitis. Maurice Hilleman at Merck used three treatments (pepsin, urea and formaldehyde) of blood serum together with rigorous filtration to yield a product that could be used as a safe vaccine. This was first licensed by the FDA in 1981. It was not very successful in the marketplace because clinicians knew that it was a product made from human blood serum. It was withdrawn from the marketplace when Pablo DT Valenzuela, Research Director of Chiron Corporation succeeded in 1986 in making the antigen in yeast and invented the first recombinant vaccine . This is the vaccine still in use today.
Recommended populations
Babies born to mothers with active hepatitis B infections are recommended to receive treatment reducing the risk of mother-to-child transmission of the hepatitis B infection. As soon as possible and within 48 hours of birth, newborns are vaccinated with hepatitis B surface antigen (HBsAg) and injected with hepatitis B immunoglobulin (HBIG).
Many countries now routinely vaccinate infants against hepatitis B. In countries with high rates of hepatitis B infection, vaccination of newborns has not only reduced the risk of infection, but has also led to marked reduction in liver cancer. This was reported in Taiwan where the implementation of a nationwide hepatitis B vaccination program in 1984 was associated with a decline in the incidence of childhood hepatocellular carcinoma.
In many areas, vaccination against hepatitis B is also required for all health-care and laboratory staff.
An Australian couple in August 2008 went on the run after the New South Wales Supreme Court extended an order forcing them to immunise their newborn against the disease. DOCS (Department of Community Services) took out the order, as doctors say the five-day-old baby is at a high risk of contracting the illness as his mother has the disease. The parents believe (see Vaccine controversy) that aluminium in the vaccine would cause the baby more harm than the disease itself.
Response to vaccination
Following the primary course of 3 vaccinations, a blood test may be taken after an interval of 1–4 months to establish if there has been an adequate response, which is defined as an anti-hepatitis B surface antigen (anti-Hbs) antibody level above 100 mIU/ml. Such a full response occurs in about 85-90% of individuals.
An antibody level between 10 and 100 mIU/ml is considered a poor response, and these people should receive a single booster vaccination at this time, but do not need further retesting.
People who fail to respond (anti-Hbs antibody level below 10 mIU/ml) should be tested to exclude current or past Hepatitis B infection, and given a repeat course of 3 vaccinations, followed by further retesting 1–4 months after the second course. Those who still do not respond to a second course of vaccination may respond to intradermal administration or to a high dose vaccine or to a double dose of a combined Hepatitis A and B vaccine. Those who still fail to respond will require hepatitis B immunoglobulin (HBIG) if later exposed to the hepatitis B virus.
Poor responses are mostly associated with being over the age of 40 years, obesity and smoking, and also in alcoholics, especially if with advanced liver disease. Patients who are immunosuppressed or on renal dialysis may respond less well and require larger or more frequent doses of vaccine. At least one study suggests that hepatitis B vaccination is less effective in patients with HIV.
Duration of protection
It is now believed that the hepatitis B vaccine provides indefinite protection. However, it was previously believed and suggested that the vaccination would only provide effective cover of between five and seven years, but subsequently it has been appreciated that long-term immunity derives from immunological memory which outlasts the loss of antibody levels and hence subsequent testing and administration of booster doses is not required in successfully vaccinated immunocompetent individuals. Hence with the passage of time and longer experience, protection has been shown for at least 25 years in those who showed an adequate initial response to the primary course of vaccinations, and UK guidelines now suggest that for initial responders who require ongoing protection, such as for healthcare workers, only a single booster is advocated at 5 years.
Safety
Several studies looked for a significant association between recombinant hepatitis B vaccine (HBV) and multiple sclerosis (MS) in adults. Most published scientific studies do not support a causal relationship between hepatitis B vaccination and demyelinating diseases such as MS. A 2004 study reported a significant increase in risk within 3 years of vaccination. Some of these studies were criticized for methodological problems. This controversy created public misgivings about HB vaccination, and hepatitis B vaccination in children remained low in several countries. A 2007 study found that the vaccination does not seem to increase the risk of a first episode of MS in childhood.
A 2009 study of the hepatitis B vaccine and associated risk of CNS inflammatory demyelination was conducted. The hepatitis B vaccine was found to be generally safe, however the Engerix B vaccine appeared to triple the risk of CNS inflammatory demyelination in infant boys. There have been numerous reports that the Hepatitis B vaccine is linked to Chronic Fatigue Syndrome, a syndrome marked by severe fatigue, brain fogs, and muscle pains among other symptoms. The Engerix B vaccine contained Thiomersal, a mercury containing vaccine preservative that is being phased out at the urging of the Public Health Service in the US.
References
- "Hepatitis B Vaccine from Merck". Retrieved 2010-05-09.
- "Hepatitis B Vaccine". Doylestown, Pennsylvania: Hepatitis B Foundation. 2009-01-31. Retrieved 2009-10-22.
- "CDC Viral Hepatitis". Atlanta, Georgia: Centers for Disease Control and Prevention. 2009-07-24. Retrieved 2009-10-22.
- The New York Times
- Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 16371945, please use {{cite journal}} with
|pmid=16371945instead. - Attention: This template ({{cite doi}}) is deprecated. To cite the publication identified by doi:10.1056/NEJM199706263362602, please use {{cite journal}} (if it was published in a bona fide academic journal, otherwise {{cite report}} with
|doi=10.1056/NEJM199706263362602instead. - Joint Committee on Vaccination and Immunisation (2006). "Chapter 12 Immunisation of healthcare and laboratory staff -- Hepatitis B". Immunisation Against Infectious Disease 2006 ("The Green Book") (3rd ed.). Edinburgh: Stationery Office. p. 468. ISBN 0113225288.
{{cite book}}:|format=requires|url=(help); External link in|chapterurl=|chapterurl=ignored (|chapter-url=suggested) (help) - "Evidence supports action against 'hep B' baby's parents: DOCS". Sydney, Australia: ABC News. 2008-08-25. Retrieved 2009-10-22.
- "Court extends order for 'hep B' baby". Croydon Park, Australia: ABC News. 2008-08-25. Retrieved 2009-10-22.
- ^ Joint Committee on Vaccination and Immunisation (2006). "Chapter 18 Hepatitis B". Immunisation Against Infectious Disease 2006 ("The Green Book") (3rd edition (Chapter 18 revised 10 October 2007) ed.). Edinburgh: Stationery Office. p. 468. ISBN 0113225288.
{{cite book}}:|format=requires|url=(help); External link in|chapterurl=|chapterurl=ignored (|chapter-url=suggested) (help) - Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 2148433, please use {{cite journal}} with
|pmid=2148433instead. - Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 7759824, please use {{cite journal}} with
|pmid=7759824instead. - Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 18544037, please use {{cite journal}} with
|pmid=18544037instead. - Attention: This template ({{cite doi}}) is deprecated. To cite the publication identified by doi:10.1001/jama.270.24.2931, please use {{cite journal}} (if it was published in a bona fide academic journal, otherwise {{cite report}} with
|doi=10.1001/jama.270.24.2931instead. - Attention: This template ({{cite doi}}) is deprecated. To cite the publication identified by doi:10.1016/S0002-9343(97)00132-0, please use {{cite journal}} (if it was published in a bona fide academic journal, otherwise {{cite report}} with
|doi=10.1016/S0002-9343(97)00132-0instead. - Attention: This template ({{cite doi}}) is deprecated. To cite the publication identified by doi:10.1186/1471-2334-6-65, please use {{cite journal}} (if it was published in a bona fide academic journal, otherwise {{cite report}} with
|doi=10.1186/1471-2334-6-65instead. Cold or Flu like symptoms can develop after receiving the vaccine, but these are short lived. As with any injection, the muscle can become tender around the injection point for some time afterwards - Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 3660859, please use {{cite journal}} with
|pmid=3660859instead. - Attention: This template ({{cite doi}}) is deprecated. To cite the publication identified by doi:10.1097/01.inf.0000130952.96259.fd, please use {{cite journal}} (if it was published in a bona fide academic journal, otherwise {{cite report}} with
|doi=10.1097/01.inf.0000130952.96259.fdinstead. - Attention: This template ({{cite doi}}) is deprecated. To cite the publication identified by doi:10.1016/j.vaccine.2007.01.045, please use {{cite journal}} (if it was published in a bona fide academic journal, otherwise {{cite report}} with
|doi=10.1016/j.vaccine.2007.01.045instead. - Attention: This template ({{cite doi}}) is deprecated. To cite the publication identified by doi:10.1016/S0140-6736(99)07239-6, please use {{cite journal}} (if it was published in a bona fide academic journal, otherwise {{cite report}} with
|doi=10.1016/S0140-6736(99)07239-6instead. - Attention: This template ({{cite doi}}) is deprecated. To cite the publication identified by doi:10.1016/j.tmaid.2006.04.004, please use {{cite journal}} (if it was published in a bona fide academic journal, otherwise {{cite report}} with
|doi=10.1016/j.tmaid.2006.04.004instead. - FAQs about Hepatitis B Vaccine (Hep B) and Multiple Sclerosis, CDC
- Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 15365133, please use {{cite journal}} with
|pmid=15365133instead. - Attention: This template ({{cite doi}}) is deprecated. To cite the publication identified by doi:10.1001/archpedi.161.12.1176, please use {{cite journal}} (if it was published in a bona fide academic journal, otherwise {{cite report}} with
|doi=10.1001/archpedi.161.12.1176instead. - "Hepatitis B vaccine and the risk of CNS inflammatory demyelination in childhood". Neurology. 2009.
- Lanctot MD, Guylaine. "Association of American Physicians&Surgeons Report". Association of American Physicians&Surgeons Report. VRAN. Retrieved 11 March 2011.
- "Thiomersal in Vaccines". U.S. Food and Drug Administration. 2010-03-31.
| Artificial induction of immunity / Immunization: Vaccines, Vaccination, Infection, Inoculation (J07) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Development | |||||||||||
| Classes | |||||||||||
| Administration | |||||||||||
| Vaccines |
| ||||||||||
| Inventors/ researchers | |||||||||||
| Controversy | |||||||||||
| Related | |||||||||||
| |||||||||||
| Genetic engineering | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Genetically modified organisms |
| ||||||||||||||||||||||||||
| Processes |
| ||||||||||||||||||||||||||
| Uses |
| ||||||||||||||||||||||||||
| Related articles | |||||||||||||||||||||||||||
| Regulation | |||||||||||||||||||||||||||
| Geography | |||||||||||||||||||||||||||
| Similar fields | |||||||||||||||||||||||||||